This clinical trial is focused on studying treatments for advanced non-small cell lung cancer (NSCLC), a type of lung cancer that is either locally advanced or has spread to other parts of the body. The study will explore new combinations of treatments to see how safe and effective they are for people who have not received prior treatment for this condition. The treatments being tested include several investigational drugs: SYM024 (also known as S095024), SYM023 (S095018), and SYM025 (S095029), all of which are given as a solution for infusion, meaning they are administered directly into the bloodstream through a vein. Additionally, a medication called cemiplimab, marketed as LIBTAYO, will be used as a control treatment in the study.

The purpose of the study is to evaluate the safety and effectiveness of these treatment combinations in patients with high levels of a protein called PD-L1 in their tumors. The study will be conducted in two parts. The first part will focus on assessing the safety of the treatment combinations and determining the appropriate dose for further testing. The second part will compare the effectiveness of the treatment combinations against cemiplimab alone. Participants will receive their assigned treatments and be monitored for any side effects and how well their cancer responds to the treatment.

Throughout the study, participants will undergo regular health checks, including blood tests and other assessments, to ensure their safety and to track the progress of their treatment. The study aims to provide valuable information on new treatment options for people with advanced NSCLC, potentially leading to better outcomes for patients in the future.